Latest research on Salbutamol

Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formulated as a racemic mixture of the R- and S-isomers. The R-isomer has 150 times greater affinity for the beta2-receptor than the S-isomer and the S-isomer has been associated with toxicity. This lead to the development of levalbuterol, the single R-isomer of salbutamol. However, the high cost of levalbuterol compared to salbutamol has deterred wide-spread use of this enantiomerically pure version of the drug. Salbutamol is generally used for acute episodes of bronchospasm caused by bronchial asthma, chronic bronchitis and other chronic bronchopulmonary disorders such as chronic obstructive pulmonary disorder (COPD). It is also used prophylactically for exercise-induced asthma.

Salbutamol dosage

In the ED, the patient was started on continuous Albuterol nebulizers and given a loading dose of terbutaline. [source, 2016]
FORM causes a fast bronchodilation that arises within a few minutes after inhalation, is dose-dependent and not significantly different from that caused by Salbutamol. [source, 2016]
Formulations of Salbutamol include pressurized metered dose inhalers (pMDIs), dry powder inhalers (DPIs), and solutions for nebulization. [source, 2016]
Several controlled clinical studies have previously compared the bronchodilating efficacy of equal single or cumulative doses of Salbutamol delivered via a standard pMDI and the DPI Easyhaler. [source, 2016]
They found 31 % presented with a hyperresponsive (>20 % drop in FEV1) reaction to inhalation of 4.5 % saline, despite a preceding dose of 200 μg Salbutamol via metered dose inhaler. [source, 2016]
Salbutamol and another β2-receptor agonist terbutaline increased MKP-1 expression alone and in combination with LPS in J774 macrophages in a dose-dependent manner (Fig 2). [source, 2016]
In order to minimize bronchoconstrictive response to saline inhalation, all subjects were premedicated with 200 µg Salbutamol via metered-dose inhaler before sputum induction12. [source, 2015]
Each measurement was performed 15 min after the inhalation of 400 μg of Salbutamol via a metered-dose inhaler. [source, 2015]
Asthma treatment approach includes the use of ‘Reliever’ for quick relief of symptoms such as the use of Salbutamol inhaler 100 µg/puff at a dose of two puffs twice or thrice daily up to a maximum of two puffs four times a day, use of ‘Controller’ for regular symptom control like beclomethasone inhaler 250 µg/puff at a dose of two puffs twice a day up to a maximum of two puffs four times a day, or long-acting β-2 agonist Salmeterol inhaler 250 µg/puff at a dose of two puffs twice a day up to a maximum of four puffs twice a day; if symptoms are not controlled, for example, occur >3 times a week, step-up treatment will be considered, and if control is maintained for ≥3 months, step-down regimen will be considered. [source, 2015]
COPD treatment will consist of Salbutamol 100 µg/puff at a dose of two puffs three or four times daily, Ipratropium 20 µg/puff at a dose of two puffs two to four times daily, or Salbutamol and Ipratropium, if symptoms persist, for more than 2 weeks on individual regimen in mild cases; Salmeterol 250 µg/puff and Fluticasone 25 µg/puff at a dose of two puffs two times daily up to a maximum of four puffs twice daily in moderate-to-severe cases; if symptoms are not adequately reduced in 2 weeks, long-acting muscarine antagonist, for example, tiotropium 18 µg capsule, would be added to the regimen once daily, or sustained release of oral Theophylline 200 mg tablet would be administered twice daily. [source, 2015]